Clarification

An Other News to Note item in the Aug. 21, 1998, issue of BioWorld Today should have said Ariad Pharmaceuticals believes it has demonstrated efficacy with its lead compound, AP22408, that would trigger a milestone payment from Hoechst Marion Roussel, of Frankfurt, Germany. Ariad is optimizing the compound in preparation for human clinical testing.